苦参素治疗乙肝所致肝纤维化的临床观察

To study clinical efficacy of kwoninone in the treatment patients with hepatic fibrosis and hepatitis B virus. Sixty patients were divided randomly into the treated group (kwoninone, 30 cases) and the controlled group (γ-interferon, 30 cases) . Four marks of hepatic fibrosis (laminin、hyaluronic acid、type Ⅲ procollagen peptide、type Ⅳ collagen) and markers of hepatitis B virus (HBsAg、HBeAg and HBV-DNA) were determined before and after treatment. Four marks of hepatic fibrosis were obviously reduced in two groups after treatment. No different significantly was found between two groups (P<0.5, P<0.25) . The result showed that the two drugs have the same curative effect in the treatment patients with hepatic fibrosis. HBsAg、HBeAg、HBV-DNA negative conversion rats of the treated group were 3.3%、22.8%、20.0% respectively. They were slightly lower than that in the controled group. The negative conversion rats of the two groups were not different significantly (P>0.5, P>0.75) . Kwoninone may be of clinical practical value in treatment hepatic fibrosis and anti-hepatitis B virus.